Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.